test
test
test
test
test
test
test
test
test
test
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
Discussion about role of DPO in Anemia management
There are 2 speakers in this webinar
A recent retrospective cohort study examined the impact of initiating anemia treatment at different hemoglobin levels on renal and cardiovascular outcomes in patients with nondialysis-dependent chronic kidney disease (NDD-CKD).
Using data from two large Japanese databases, the study evaluated patients treated with long-acting erythropoiesis-stimulating agents (ESAs), dividing them into early treatment (hemoglobin ≥9.0 g/dl) and delayed treatment (<9.0 g/dl) groups.
The primary outcome was a renal composite, including renal replacement therapy, significant reduction in estimated glomerular filtration rate (eGFR), and all-cause mortality. Secondary outcomes focused on cardiovascular events such as heart failure, stroke, and cardiovascular death.
After propensity score matching, results from 1472 (MDV) and 1264 (RWD) patients revealed that delayed treatment did not significantly raise the risk of renal events (MDV HR: 1.15; RWD HR: 1.08). However, delayed anemia treatment was associated with a substantial increase in cardiovascular risks, including heart failure (MDV HR: 1.50; RWD HR: 1.53), as well as higher all-cause mortality (MDV HR: 1.83; RWD HR: 1.64).
The findings suggest that while renal outcomes may remain unaffected, delaying anemia treatment in NDD-CKD patients can significantly increase cardiovascular risks and mortality, highlighting the importance of early intervention before hemoglobin drops below 9.0 g/dl.
A recent retrospective cohort study examined the impact of initiating anemia treatment at different hemoglobin levels on renal and cardiovascular outcomes in patients with nondialysis-dependent chronic kidney disease (NDD-CKD).
Using data from two large Japanese databases, the study evaluated patients treated with long-acting erythropoiesis-stimulating agents (ESAs), dividing them into early treatment (hemoglobin ≥9.0 g/dl) and delayed treatment (<9.0 g/dl) groups.
The primary outcome was a renal composite, including renal replacement therapy, significant reduction in estimated glomerular filtration rate (eGFR), and all-cause mortality. Secondary outcomes focused on cardiovascular events such as heart failure, stroke, and cardiovascular death.
After propensity score matching, results from 1472 (MDV) and 1264 (RWD) patients revealed that delayed treatment did not significantly raise the risk of renal events (MDV HR: 1.15; RWD HR: 1.08). However, delayed anemia treatment was associated with a substantial increase in cardiovascular risks, including heart failure (MDV HR: 1.50; RWD HR: 1.53), as well as higher all-cause mortality (MDV HR: 1.83; RWD HR: 1.64).
The findings suggest that while renal outcomes may remain unaffected, delaying anemia treatment in NDD-CKD patients can significantly increase cardiovascular risks and mortality, highlighting the importance of early intervention before hemoglobin drops below 9.0 g/dl.
A recent retrospective cohort study examined the impact of initiating anemia treatment at different hemoglobin levels on renal and cardiovascular outcomes in patients with nondialysis-dependent chronic kidney disease (NDD-CKD).
Using data from two large Japanese databases, the study evaluated patients treated with long-acting erythropoiesis-stimulating agents (ESAs), dividing them into early treatment (hemoglobin ≥9.0 g/dl) and delayed treatment (<9.0 g/dl) groups.
The primary outcome was a renal composite, including renal replacement therapy, significant reduction in estimated glomerular filtration rate (eGFR), and all-cause mortality. Secondary outcomes focused on cardiovascular events such as heart failure, stroke, and cardiovascular death.
After propensity score matching, results from 1472 (MDV) and 1264 (RWD) patients revealed that delayed treatment did not significantly raise the risk of renal events (MDV HR: 1.15; RWD HR: 1.08). However, delayed anemia treatment was associated with a substantial increase in cardiovascular risks, including heart failure (MDV HR: 1.50; RWD HR: 1.53), as well as higher all-cause mortality (MDV HR: 1.83; RWD HR: 1.64).
The findings suggest that while renal outcomes may remain unaffected, delaying anemia treatment in NDD-CKD patients can significantly increase cardiovascular risks and mortality, highlighting the importance of early intervention before hemoglobin drops below 9.0 g/dl.
This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia.
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01).
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.
This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia.
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01).
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.
This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia.
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01).
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.
This double-blind, randomized, controlled trial examined the impact of vitamin D supplementation on anemia management in hemodialysis (HD) patients with end-stage renal disease (ESRD) and vitamin D deficiency.
One hundred anemic HD patients with vitamin D deficiency were randomly assigned to receive either monthly vitamin D (50,000 IU) or a placebo for six months. Serum 25-hydroxyvitamin D (25(OH)D) levels were measured at baseline and after six months, while hemoglobin (Hb) concentrations were monitored monthly.
Results demonstrated that vitamin D supplementation significantly increased 25(OH)D levels in the treatment group compared to the placebo group (p > 0.001). While serum ferritin, serum iron, and transferrin saturation did not differ significantly between the groups, Hb concentrations in the vitamin D group rose significantly more than in the placebo group throughout the study period.
Additionally, erythropoietin (EPO) dosage requirements were notably lower in the vitamin D group compared to the placebo group (p > 0.001).
These findings indicate that vitamin D supplementation is a safe and effective approach to improving anemia in HD patients with vitamin D deficiency, reducing the need for EPO therapy, and enhancing overall anemia management in this vulnerable population.
This double-blind, randomized, controlled trial examined the impact of vitamin D supplementation on anemia management in hemodialysis (HD) patients with end-stage renal disease (ESRD) and vitamin D deficiency.
One hundred anemic HD patients with vitamin D deficiency were randomly assigned to receive either monthly vitamin D (50,000 IU) or a placebo for six months. Serum 25-hydroxyvitamin D (25(OH)D) levels were measured at baseline and after six months, while hemoglobin (Hb) concentrations were monitored monthly.
Results demonstrated that vitamin D supplementation significantly increased 25(OH)D levels in the treatment group compared to the placebo group (p > 0.001). While serum ferritin, serum iron, and transferrin saturation did not differ significantly between the groups, Hb concentrations in the vitamin D group rose significantly more than in the placebo group throughout the study period.
Additionally, erythropoietin (EPO) dosage requirements were notably lower in the vitamin D group compared to the placebo group (p > 0.001).
These findings indicate that vitamin D supplementation is a safe and effective approach to improving anemia in HD patients with vitamin D deficiency, reducing the need for EPO therapy, and enhancing overall anemia management in this vulnerable population.
This double-blind, randomized, controlled trial examined the impact of vitamin D supplementation on anemia management in hemodialysis (HD) patients with end-stage renal disease (ESRD) and vitamin D deficiency.
One hundred anemic HD patients with vitamin D deficiency were randomly assigned to receive either monthly vitamin D (50,000 IU) or a placebo for six months. Serum 25-hydroxyvitamin D (25(OH)D) levels were measured at baseline and after six months, while hemoglobin (Hb) concentrations were monitored monthly.
Results demonstrated that vitamin D supplementation significantly increased 25(OH)D levels in the treatment group compared to the placebo group (p > 0.001). While serum ferritin, serum iron, and transferrin saturation did not differ significantly between the groups, Hb concentrations in the vitamin D group rose significantly more than in the placebo group throughout the study period.
Additionally, erythropoietin (EPO) dosage requirements were notably lower in the vitamin D group compared to the placebo group (p > 0.001).
These findings indicate that vitamin D supplementation is a safe and effective approach to improving anemia in HD patients with vitamin D deficiency, reducing the need for EPO therapy, and enhancing overall anemia management in this vulnerable population.
Anemia and chronic kidney disease (CKD) are known to worsen outcomes following acute myocardial infarction (AMI). This retrospective, single-center study evaluated the interaction between anemia and CKD in predicting 10-year survival among AMI survivors. The cohort consisted of 11,395 patients (69.1% male, mean age 65.8 years), stratified by anemia and CKD grade based on admission hemoglobin and creatinine levels.
Among participants, 29.9% had anemia and 15.9% had CKD grade 3b or higher. Anemia prevalence increased with advancing CKD grade (p < 0.001), and CKD was more severe in anemic patients. After a decade, 47.8% of the cohort had died. Despite varying baseline characteristics and treatment approaches, both anemia (HR 1.40, 95% CI 1.32-1.49, p < 0.001) and higher CKD grades (HR 1.10, 95% CI 1.02-1.20, p < 0.001) independently predicted increased mortality risk.
The mortality risk due to anemia or worsening CKD was particularly evident in patients with normal renal function to CKD grade 3a in the overall cohort and conservative treatment subgroup, and up to grade 4 in the invasive revascularization subgroup. Notably, higher CKD grades also elevated mortality risk among non-anemic patients across CKD stages.
In conclusion, anemia and advancing CKD independently contribute to reduced long-term survival following AMI, with the combined effect posing the greatest risk in patients with mild to moderate CKD.
Anemia and chronic kidney disease (CKD) are known to worsen outcomes following acute myocardial infarction (AMI). This retrospective, single-center study evaluated the interaction between anemia and CKD in predicting 10-year survival among AMI survivors. The cohort consisted of 11,395 patients (69.1% male, mean age 65.8 years), stratified by anemia and CKD grade based on admission hemoglobin and creatinine levels.
Among participants, 29.9% had anemia and 15.9% had CKD grade 3b or higher. Anemia prevalence increased with advancing CKD grade (p < 0.001), and CKD was more severe in anemic patients. After a decade, 47.8% of the cohort had died. Despite varying baseline characteristics and treatment approaches, both anemia (HR 1.40, 95% CI 1.32-1.49, p < 0.001) and higher CKD grades (HR 1.10, 95% CI 1.02-1.20, p < 0.001) independently predicted increased mortality risk.
The mortality risk due to anemia or worsening CKD was particularly evident in patients with normal renal function to CKD grade 3a in the overall cohort and conservative treatment subgroup, and up to grade 4 in the invasive revascularization subgroup. Notably, higher CKD grades also elevated mortality risk among non-anemic patients across CKD stages.
In conclusion, anemia and advancing CKD independently contribute to reduced long-term survival following AMI, with the combined effect posing the greatest risk in patients with mild to moderate CKD.
Anemia and chronic kidney disease (CKD) are known to worsen outcomes following acute myocardial infarction (AMI). This retrospective, single-center study evaluated the interaction between anemia and CKD in predicting 10-year survival among AMI survivors. The cohort consisted of 11,395 patients (69.1% male, mean age 65.8 years), stratified by anemia and CKD grade based on admission hemoglobin and creatinine levels.
Among participants, 29.9% had anemia and 15.9% had CKD grade 3b or higher. Anemia prevalence increased with advancing CKD grade (p < 0.001), and CKD was more severe in anemic patients. After a decade, 47.8% of the cohort had died. Despite varying baseline characteristics and treatment approaches, both anemia (HR 1.40, 95% CI 1.32-1.49, p < 0.001) and higher CKD grades (HR 1.10, 95% CI 1.02-1.20, p < 0.001) independently predicted increased mortality risk.
The mortality risk due to anemia or worsening CKD was particularly evident in patients with normal renal function to CKD grade 3a in the overall cohort and conservative treatment subgroup, and up to grade 4 in the invasive revascularization subgroup. Notably, higher CKD grades also elevated mortality risk among non-anemic patients across CKD stages.
In conclusion, anemia and advancing CKD independently contribute to reduced long-term survival following AMI, with the combined effect posing the greatest risk in patients with mild to moderate CKD.
